Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NWSxfZpROjV7NkCyPFI>
KellyCis83 M1LkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTjTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= NXjTZlRKOjV7NkCyPFI>
SK-N-AS M4HBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTuPId2UUN3ME2wMlI16oDLwsJihKkxNjB|IN88US=> M1TJN|I2QTZyMkiy
SK-N-ASCis24 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq1c5BKSzVyPUCuOVfjiIoEsfMAjVAvOTFizszN M1;TSlI2QTZyMkiy
U87 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXiNE02OCEQvF2= M4TSblQ5KGh? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KHOrbHnibY5qdg>? Mn;DNlU4PTB{N{O=
HCT116 NI\PWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jOeVAvPS1{LkWg{txO MYO0POKhcMLi NITibWtKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NVnG[|A3OjV5NE[3OlM>
HT-29 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7FNE42NTJwNTFOwG0> MmKxOFjDqGkEoB?= NFvmSGNKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= NX3rNnJXOjV5NE[3OlM>
Caco2 NVjwN2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PBSFAvPS1{LkWg{txO NHT1OWQ1QMLiaNMg NHS1NXlKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= NG\XNpQzPTd2Nke2Ny=>
COLO 205 NX;hepp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTF[HlMOC53LUKuOUDPxE1? M{HQeFQ5yqCqwrC= NHvrco5KSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= MV:yOVc1Pjd4Mx?=
SW480 NUnvRlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMlUuOi53IN88US=> Mn7xOFjDqGkEoB?= Ml7UTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M2i5XlI2PzR4N{[z
HEK293T NFrrcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xMVUh|ryP MXK0POKhcMLi MVTJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? Mn7uNlU4PDZ5NkO=
Hep3B  NGjsWGlHfW6ldHnvckBCe3OjeR?= NEnpd4UyOCEQvF2= MWm0POKhcMLi MXry[YR2[2W|IITo[UBmdmijbnPpcoch\W[oZXP0JI9nKEKPUD22 M4jlZlI2PjN|NU[0
Hep3B  NU\jTFlwTnWwY4Tpc44hSXO|YYm= MnjxNE4yNTFyIN88US=> M2fISlI1KGh? NWiyPHJLe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B Mo\sNlU3OzN3NkS=
HEK293 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP M1jPXVI2PjB|MUKy
DU145 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjNbXVKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= MYWyOVYxOzF{Mh?=
HCT15 NXPSTWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zoUWlEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= Mn\HNlU3ODNzMkK=
T47D NFTUSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? NV\pNmpyOjV4MEOxNlI>
SMMC-7721 MXTGeY5kfGmxbjDBd5NigQ>? Mn3iOFAh|ryP M4jySFQ5KGh? MkPISG1UVw>? NXfROGdmcW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? M1fQU|I2PTR2M{[x
MDA-MB-231 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;pb3NNPzMEoHi= MnTUTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? NWXQbm1qOjV2OE[yNVk>
MCF-7 NFjEdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlroO|LDqGh? M3j6d2lEPTB;MUCuPeKhyrIEoEKuNeKh|ryP M3vC[FI2PDh4MkG5
Jurkat NHf0[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NuKhcA>? M4HhVmlEPTB;MT6yxsDDucLiMT61xsDPxE1? M2fs[lI2PDh4MkG5
HeLa NYXzZnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLiO|LDqGh? MnzETWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? M334ZVI2PDh4MkG5
MCF7  NV3zT3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\WOU0yODBizszN NIS3V5c4KGR? M{DXPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mnr6NlU1PzJ4MUm=
K562 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSzO|LDqGh? MlnqTWM2OD1yLkK5xsDPxE1? M2POXFI2Ojh{NkWz
K/VP.5 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi3NuKhcA>? M4O1TmlEPTB;ND65xsDPxE1? MknmNlUzQDJ4NUO=
SH-EP  M{jWSWZ2dmO2aX;uJGF{e2G7 MYOyNOKh|rypL33s MkPwNlTDqGh? NX\DR|JHcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> M3vBcVI2OjZzOUix
SCC25 NH2we3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX1NFZIOjUEoHi= NIX5NmFKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= NHzNfZIzPTJ{MEeyPS=>
CAL27 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDHTGtJOjUEoHi= NYLVcIdWUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN NE\QSVMzPTJ{MEeyPS=>
FaDu NXv3ZnJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWyZVY4OjUEoHi= MYrJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP MlvpNlUzOjB5Mkm=
SCC25 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FOFjDqGh? NUL3boxXUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> NEfobVAzPTJ{MEeyPS=>
CAL27 MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvaR5Q1QMLiaB?= NEnEZWtKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN NW\NR5dlOjV{MkC3Nlk>
FaDu NYrsOpZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnuWWF1PDkEoHi= NHLRcWRKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= M2LmU|I2OjJyN{K5
SCC25 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX76cG54PzMEoHi= NY\Tb2Q5UUN3ME24MlQyyqEEsdMgNU4yOcLizszN MUeyOVIzODd{OR?=
CAL27 NILxe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64U|JXPzMEoHi= MWPJR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? MUeyOVIzODd{OR?=
FaDu NFG5WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPQO|LDqGh? MV;JR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? Ml7iNlUzOjB5Mkm=
MCF-7 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4eo01QMLiaNMg NUOxS4tYTE2VTx?= MofZTWM2OD15LkNCpOKyyqByLklCpO69VQ>? Mo\WNlUzOTZ|N{i=
T-47D NUn4O5dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL6OFjDqGkEoB?= M3vLPGROW09? MmfoTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? MnqyNlUzOTZ|N{i=
MDA-MB-231 NWXxN|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33LPVQ5yqCqwrC= NU\zV3o4TE2VTx?= MXLJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? NUP0RoJQOjV{MU[zO|g>
DU145 MYnBdI9xfG:|aYOgRZN{[Xl? NYnqPJpWOTBvMUCwJO69VQ>? NXvKTVNUQCCq NIi5SmxFVVOR NEnPPIhqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NV;4ZmN2OjVzNEm2PFE>
DU145 stem-like MmDLRZBweHSxc3nzJGF{e2G7 MlHsNVAuOTByIN88US=> MkeyPEBp MlqxSG1UVw>? NFvxXlFqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF\NfI4zPTF2OU[4NS=>
DU145 M{HTT2Z2dmO2aX;uJGF{e2G7 NWX4[GVbOTBvMUCwJO69VQ>? MluyNkBp NIjOUYpFVVOR M1XuXolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmHRNlUyPDl4OEG=
DU145 stem-like NXuzWZozTnWwY4Tpc44hSXO|YYm= NIrWRlYyOC1zMECg{txO NHqwe3czKGh? MnrUSG1UVw>? NVHqW5BncW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlHWNlUyPDl4OEG=
UW228-3 NGrrTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvLclhHOC5yMT2zNFAh|ryP NEPOUo81QCCq NVu1UW1[TE2VTx?= MWDJR|UxRTBwOUpCpO69VQ>? MXuyOVEyQTF6NR?=
NSCs M3TSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XvNVAvODFvM{CwJO69VQ>? M1nWNFQ5KGh? NF[wPZFFVVOR NILJfohKSzVyPUCuN{0{yqEQvF2= MWKyOVEyQTF6NR?=
MKL-1  M3K2e2Z2dmO2aX;uJGF{e2G7 MW[xNE0yODByIH7N MYW0JIQ> MXvpcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NH:3WVEzPTFzNke1OC=>
MCF7 EV M1T1e2Z2dmO2aX;uJGF{e2G7 Mof2NVAuOTByIN88US=> M{DOXVLjiImq NVPWZnlJcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NYDs[ZN2OjVyOEiyNFM>
MCF 7BMI1 NUPnNmdMTnWwY4Tpc44hSXO|YYm= NEfY[4kyOC1zMECg{txO NV7Yc|R2OuLCiXi= Mor2bY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> MkjYNlUxQDh{MEO=
MCF7 EV NIPZWpFHfW6ldHnvckBCe3OjeR?= NY\iUWdFOTBvMUCwJO69VQ>? NXmzS3lmOuLCiXi= MoCySXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NX3vRZBTOjVyOEiyNFM>
MCF7 BMI1 MXTGeY5kfGmxbjDBd5NigQ>? NHHS[5EyOC1zMECg{txO MnW0NwKBkWh? NFL6fIFGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MnG1NlUxQDh{MEO=
HepG2 NVfrSGNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv5UoxFVVORwrC= M2eySGlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= NYflWoNGOjVyN{izNVE>
MOLT-3 NXiybolNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjEUXNQyqB? MYjJR|UxRTBwMEWxxsDDucLiMD6wNFLDqM7:TR?= NWe3U5gzOjVyN{izNVE>
HT1080 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;TdXcyNTFyMDFOwG0> M2i1dVQwOjRxNEigbC=> MoH3SG1UV8Li NHvqO4ZqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= M1vMclI2ODd6ME[0
HT1080 MnvsSpVv[3Srb36gRZN{[Xl? Mlv4NE4xODBzLUGwNEDPxE1? MmLuNU0zPCCq Ml;nSG1UV8Li Mn7CbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NILYXmczPTB5OEC2OC=>
HT1080 M13HcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HzNFAvODByMT2xNFAh|ryP MWiyOEBp MUnEUXNQyqB? NVW5VGlW[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> NWr1fmhnOjVyN{iwOlQ>
HD-MY-Z Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuyOE81QC95MjDo M2fLeWlEPTExvK6xNFAh|ryP MWOyOVA1QDJ|Nh?=
DOHH-2 NWjuTGlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX75[|VOOjRiaB?= MkLsTWM2OO,:nkGwNEDPxE1? M1e2UVI2ODR6MkO2
DOHH-2 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC0PEBp M{C0W2lEPTB;MUmuPeKh|ryP NGPYcHUzPTB2OEKzOi=>
DOHH-2 M2i5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITa[|k4OiCq NXvJ[nlFUUN3ME21xsDPxE1? M1HGfFI2ODR6MkO2
REH NU\VNVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKNlQhcA>? NULWUXJ1UUN3ME2wMlAzP8LizszN NFvnXIgzPTB2OEKzOi=>
REH Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzTNZI1QCCq MWDJR|UxRTBwMEG0xsDPxE1? MWqyOVA1QDJ|Nh?=
REH MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nmRVczKGh? MYHJR|UxRTBwMEG1xsDPxE1? NX\O[45ROjVyNEiyN|Y>
HH NEjI[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Mc5czPCCq M2P4[GlEPTB;MUC0MlfDqM7:TR?= NUL6TXdmOjVyNEiyN|Y>
HH M1\uTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjhbFdvPDhiaB?= MYfJR|UxRTR6LkdCpO69VQ>? M1T0SVI2ODR6MkO2
HH NYHEeZZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS3NkBp NVradG57UUN3ME2xOE44yqEQvF2= NEDOfZgzPTB2OEKzOi=>
HuT-78 M4Tn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmyOEBp MoHNTWM2OD17LkRCpO69VQ>? MmT4NlUxPDh{M{[=
HuT-78 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX0VIk1QCCq MWjJR|UxRTRwM9Mg{txO MnrLNlUxPDh{M{[=
HuT-78 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3NkBp NGf3ZVdKSzVyPUSuNuKh|ryP M1j4SlI2ODR6MkO2
OPM-2 NIjaSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe3ToszPCCq M3LFUWlEPTB;MkSuNeKh|ryP MUeyOVA1QDJ|Nh?=
OPM-2 NWK3WWpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHyS3c1QCCq NVfOO|BlUUN3ME20xsDPxE1? M1LVclI2ODR6MkO2
OPM-2 NH7pWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonsO|IhcA>? NUnD[ItMUUN3ME2xMlPDqM7:TR?= MoP6NlUxPDh{M{[=
RPMI-8226 NHzoelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy2S3ozPCCq NVj5U5NNUUN3ME2xNFYvPsLizszN NG\V[VIzPTB2OEKzOi=>
RPMI-8226 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HOTlQ5KGh? NWXo[oVHUUN3ME25NU4yyqEQvF2= NIjUT2EzPTB2OEKzOi=>
RPMI-8226 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPtO|IhcA>? M{TVc2lEPTB;MUSuPeKh|ryP MV:yOVA1QDJ|Nh?=
U-266 NFvQPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO4cnRzOjRiaB?= NFfzd|RKSzVyPUi2MlLDqM7:TR?= MV:yOVA1QDJ|Nh?=
U-266 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHDVndqPDhiaB?= M1rnbmlEPTB;NkiuOOKh|ryP NHj2R5czPTB2OEKzOi=>
U-266 NVvLeWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDHO|IhcA>? MYLJR|UxRTJ5LkVCpO69VQ>? M2nLZlI2ODR6MkO2
Kelly NGHXTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrJfZV4OC1zMDFOwG0> MVG3NuKhcA>? M1m2eGlEPTB;MT61NVjDqM7:TR?= Mnj3NlUxODh7MEC=
SH-SY5Y  M1XrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnuS2RyOC1zMDFOwG0> NInVNG44OsLiaB?= NWTBe|g4UUN3ME2wMlc2PMLizszNxsA> NUXzOIJ1OjVyMEi5NFA>
SK-N-AS NHTYendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjr[JJ3OC1zMDFOwG0> NF[wPHk4OsLiaB?= NIqzTFZKSzVyPUGuO|EzyqEQvF5CpC=> MmDUNlUxODh7MEC=
SK-N-DZ M4fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLYZ49IOC1zMDFOwG0> M2XQWVczyqCq MYHJR|UxRTVwNEi1xsDPxE1? MlrRNlUxODh7MEC=
HepG2 NF7xb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfiXolzPDkEoHi= NGfVd5RFVVORwrC= M4ezeWlEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= MXeyOFk6PjF|Nh?=
A549 NF;XeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXoOFjDqGh? MUnEUXNQyqB? NI[1fWpKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NX;i[3VqOjR7OU[xN|Y>
MCF7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jHNlQ5yqCq MV\EUXNQyqB? MnjNTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= NWLvXZBwOjR7OU[xN|Y>
HL-60  NI\hb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtZ4g4OsLiaB?= NGD5[2tKSzVyPUCuNVLjiIYQvF2= M1jlbFI1QTl|MEG0
HL-60[R] M3L4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK0cY84OsLiaB?= M4LlPGlEPTB;Mz6xNwKBjc7:TR?= M2fZZVI1QTl|MEG0
MIAPACA NU\kfmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7hT3ZIUTVyPUGuN{DDuSByLkCzJO69VQ>? M4TKOVI1QTV|OEKx
MCF-7 NHLmWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITSclRIUTVyPUCuNlUhyrFiMD6xJO69VQ>? M1\6[|I1QTV|OEKx
HeLa NIDOe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLrT2k5T0l3ME2wMlY1KMLzIECuOEDPxE1? M1m4XFI1QTV|OEKx
MO59K  NWTYdVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HwO|ch\A>? MmraTWM2OD1yLkG35qCG|ryP MU[yOFk2OzV4MR?=
MO59J M3Hib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPpO{Bl MofhTWM2OD1yLkJihKXPxE1? NG\CN4ozPDl3M{W2NS=>
ME 180 NIDHW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDWR2E1QMLiaNMg NGLOem5KSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= M1rjXVI1QTV|MEK3
MCF-7 NX3UbZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvSOFjDqGkEoB?= NVfVUlNIUUN3ME2yN{46KMLzIECuN-KBjc7:TR?= MVeyOFk2OzB{Nx?=
HeLa Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[0OFjDqGkEoB?= NXLJR2x6UUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MWKyOFk2OzB{Nx?=
MDA-MB-453 NInESpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS0POKhcMLi NUHQWIpLUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= Mkm4NlQ6PTNyMke=
MDA-MB-231 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqSVlCPDkEoHlCpC=> MmH4TWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP M4LuUVI1QTV|MEK3
PC-3 NVzuTIxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfnVnV[PDkEoHlCpC=> NYPZe4xqUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= M1e0UFI1QTV|MEK3
HT-29 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ZOFjDqGkEoB?= NWjQS2tpUUN3ME2yNU41PSEEsTCzMlg46oDHzszN MnLONlQ6PTNyMke=
BGC-823 MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nEeVQ5yqCqwrC= NUjSU3F4UUN3ME20N{44PCEEsTC1MlE{6oDHzszN NHPSPZQzPDd7M{i3Oy=>
HeLa MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG0POKhcMLi MlOzTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN NVi5O|dZOjR5OUO4O|c>
A549 NXHFWFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWzR5c1QMLiaNMg MonVTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= M4rBWVI1Pzl|OEe3
HK-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXqOFjDqGkEoB?= MYrJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? NXzLTJdNOjR5OUO4O|c>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 5% DMSO+30% PEG 300+H2O 15mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID